ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

Core Insights - ALX Oncology has appointed Harish Shantharam as Chief Financial Officer and added Barbara Klencke, M.D., and Chris H. Takimoto, M.D., Ph.D., FACP, to its Board of Directors, enhancing its leadership team as it prepares for late-stage clinical trials of its lead candidate evorpacept in 2025 [1][2] Company Leadership - Harish Shantharam brings over 20 years of experience in financial and commercial functions within the biotech sector, having previously served as CFO at CymaBay Therapeutics and held significant roles at Gilead Sciences, where he managed financial operations for a $20-$30 billion revenue business [3][5] - Barbara Klencke, M.D., has over 30 years of experience in oncology and has contributed to the development and commercialization of various oncology products, including roles at Sierra Oncology and Onyx Pharmaceuticals [4][5] - Chris H. Takimoto, M.D., Ph.D., FACP, has over 30 years of experience in oncology and pharmacology, previously serving as Chief Medical Officer at IGM Biosciences and Forty Seven, and has a strong background in clinical development [6][5] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on therapies that enhance the immune system to treat cancer, with its lead candidate evorpacept being evaluated in multiple clinical trials across various cancer indications [7]